ライフサイエンスコーパス: pioglitazone

1 on exenatide, 166 on sitagliptin, and 165 on pioglitazone).

2 drome, with the thiazolidinedione class drug pioglitazone.

3 class of anti-diabetic medications including pioglitazone.

4 ned CMR, up to 4.7 years after withdrawal of pioglitazone.

5 omologs, E75 and E78, are in vivo targets of pioglitazone.

6 to those from an equivalent dose of racemic pioglitazone.

7 tor dapagliflozin and the insulin sensitizer pioglitazone.

8 treatment with the insulin-sensitizing agent pioglitazone.

9 r changes were observed in mice treated with pioglitazone.

10 a novel target of the type II diabetes drug pioglitazone.

11 nsulin sensitivity was seen after 21 days of pioglitazone.

12 in obese mice by the thiazolidinedione drug pioglitazone.

13 tidiabetes drugs including rosiglitazone and pioglitazone.

14 get for a commonly prescribed diabetes drug, Pioglitazone.

15 matory, an effect enhanced by treatment with pioglitazone.

16 2 to receive sitagliptin, and 172 to receive pioglitazone.

17 n=13, 8%) were the most frequent events with pioglitazone.

18 s (T2DM) seem to be specifically targeted by pioglitazone.

19 d and T cell proliferation was unaffected by pioglitazone.

20 63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin ve

21 74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin ve

22 rms (vildagliptin: -0.1%+/-0.3%; P=0.046 and pioglitazone: -0.2%+/-0.3%; P=0.029).

23 n, 15.4 [5.5] vs 4.5 [2.4] mug/mL, P < .001; pioglitazone, 12.6 [3.6] vs 4.8 [0.6] mug/mL, P < .001).

24 roups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).

25 rmin, 1.8 at study entry to 0.1 at month 24; pioglitazone, 2.2 at study entry to 0.3 at month 24).

26 rmin, 2.5 at study entry to 0.5 at month 24; pioglitazone, 2.3 at study entry to 0.6 at month 24), as

27 e (vildagliptin: -20+/-24 mg/dL; P=0.002 and pioglitazone: -23+/-29 mg/dL; P=0.004), and pioglitazone

28 a-2a plus ribavirin for 48 weeks, n = 73) or pioglitazone 30-45 mg/day plus standard care (n = 77) in

29 ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg/kg).

30 in, 5.5 [2.4] vs 10.5 [3.4] ng/mL, P < .001; pioglitazone, 4.1 [0.8] vs 11.0 [2.6] ng/mL, P < .001) a

31 rticipants were randomly assigned to receive pioglitazone (45 mg/d target dose) or placebo within 180

32 aloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followe

33 Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatmen

34 metformin, 6.7 [1.5] vs 2.1 [1.0], P = .001; pioglitazone, 6.9 [0.8] vs 3.0 [0.8], P = .001).

35 by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25

36 We hypothesized that pioglitazone, a peroxisome proliferator-activated recept

37 dition of lipids, and studied the effects of pioglitazone, a peroxisome proliferator-activated recept

38 was restored in cells that were treated with pioglitazone, a PPARgamma agonist, before infection with

39 Short-term exposure to pioglitazone, a PPARgamma agonist, had no effect on mort

40 Importantly, our data show that pioglitazone, a PPARgamma agonist, significantly inhibit

41 Here we have shown that pioglitazone, a selective peroxisome proliferative-activ

42 In conclusion, pioglitazone acutely induces whole-body metabolic slowin

43 to determine if the insulin-sensitizing drug pioglitazone acutely reduces insulin secretion and cause

44 as reduced in both Wistar and ZDF rats after pioglitazone administration.

45 from WT mNT to mitochondria, indicating that pioglitazone affects a specific property, [2Fe-2S] clust

46 e proliferator-activated receptor-gamma with pioglitazone alone is not sufficient to promote differen

47 Pioglitazone also reduced energy expenditure in Wistar r

48 Pioglitazone also reduced the risk of type 1 MI (hazard

49 pioglitazone: -23+/-29 mg/dL; P=0.004), and pioglitazone also significantly improved fasting plasma

50 ile-infected mice with the PPARgamma agonist pioglitazone ameliorated colitis and suppressed pro-infl

51 se treatment of diabetic obese patients with pioglitazone, an antidiabetic and antiinflammatory PPARg

52 The PPARgamma agonist pioglitazone and a novel selective PPARalpha/gamma modul

53 gamma binding assays (affinity comparable to pioglitazone and arachidonic acid), and in vitro murine

54 uced TFH cell responses in female mice while pioglitazone and estradiol (E2) co-treatment ameliorated

55 tablished treatments for insulin resistance (pioglitazone and exenatide) as possible disease modifyin

56 om 2004-2010, we analyzed the association of pioglitazone and incidence of dementia in a prospective

57 a is activated by thiazolidinediones such as pioglitazone and is targeted to treat insulin resistance

58 g Administration-approved thiazolidinediones pioglitazone and rosiglitazone are peroxisome proliferat

59 Previously, we reported that pioglitazone and rosiglitazone induce osteocyte apoptosi

60 The use of pioglitazone and rosiglitazone is associated with a decr

61 Pioglitazone and rosiglitazone possess a common function

62 tration of synthetic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates PPAR-gamma-

63 currently marketed PPARgamma full agonists, pioglitazone and rosiglitazone, have been reported to pr

64 s of two variants of the glitazone scaffold, pioglitazone and rosiglitazone, in an effort to identify

65 f specific cancer types may be different for pioglitazone and rosiglitazone.

66 -3.5 +/- 1.71 and -3.7 +/- 1.62 IU/mL in the pioglitazone and standard-care groups, respectively, Del

67 atohepatitis [NASH]) trial demonstrated that pioglitazone and vitamin E improved liver histology to v

68 lycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cho

69 ith prescriptions of <8 calendar quarters of pioglitazone, and diabetics with >/=8 quarters.

70 ments with proven benefit include vitamin E, pioglitazone, and obeticholic acid; however, the effect

71 mice were treated with the PPARgamma agonist pioglitazone, and phagocyte ROS and killing of S aureus

72 FP to inhibit the pro-adipogenic response to pioglitazone, and that the ability of pioglitazone to de

73 PPAR-gamma agonists, like pioglitazone, appear antiproteinuric.

74 Pioglitazone appeared to have its most prominent effect

75 The effect of pioglitazone appears to be a direct action on beta cells

76 ed receptor (PPAR) gamma agonists, including pioglitazone, approved for type 2 diabetes therapy alter

77 PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use for the treatment of in

78 data demonstrate that both vildagliptin and pioglitazone are of potential benefit in patients with I

79 dinediones (TZDs), such as rosiglitazone and pioglitazone, are peroxisome proliferator-activated rece

80 , and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP.

81 Treatment with pioglitazone as compared with placebo was associated wit

82 mpounds, we identified the PPARgamma agonist pioglitazone as neuroprotective in Drosophila.

83 umulative dose, and time since initiation of pioglitazone as time dependent.

84 )=0.960, P<0.0001) 12weeks of treatment with pioglitazone as well as from control subjects (R(2)=0.89

85 atohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vit

86 c-euglycemic clamp was minimally affected by pioglitazone at this early time point.

87 Treatment with pioglitazone before and during treatment with peginterfe

88 HDL cholesterol levels who were treated with pioglitazone, but not in patients with hypercholesterole

89 placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mell

90 Here, we show that pioglitazone can rescue TDP-43-dependent locomotor dysfu

91 roach, we identify a set of metabolites that pioglitazone can restore in the context of TDP-43 expres

92 or MI derive a greater absolute benefit from pioglitazone compared with patients at lower risk.

93 Islets from animals treated with pioglitazone concurrently with HFD demonstrated a revers

94 e findings together suggest that repurposing pioglitazone could potentially enhance the proteinuria-r

95 F11 genetic deficiency effectively abolished pioglitazone cytoprotection in mouse cerebral vascular e

96 Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or n

97 that, in L6 cells, rosiglitazone- as well as pioglitazone-dependent activation of peroxisome prolifer

98 shed between nondiabetics, diabetics without pioglitazone, diabetics with prescriptions of <8 calenda

99 esults show that stimulation of PPARgamma by pioglitazone did not affect basal anxiety, but fully pre

100 ients with a recent ischaemic stroke or TIA, pioglitazone did not affect cognitive function, as measu

101 kinase/c-Jun NH(2)-terminal kinase, whereas pioglitazone did not, and dexamethasone deactivated to s

102 Troglitazone and pioglitazone differ in their influence on SSC.

103 ic monophosphate sodium salt (8-Br-cGMP), or pioglitazone dose-dependently downregulated podocyte inj

104 ypothesis, female NOD mice were administered pioglitazone during the pre-diabetic phase and assessed

105 glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonog

106 and shRNA knockdown of PPFP eliminated this pioglitazone effect.

107 ion; however, when combined, cholesterol and pioglitazone enhance OPC differentiation into mature OLs

108 lysis revealed that both glucocorticoids and pioglitazone enhanced glomerular synaptopodin and nephri

109 rt-term treatment of gp91(phox-/-) mice with pioglitazone enhanced stimulated ROS production in neutr

110 act as a stereoselective barrier to prevent pioglitazone entry into the brain.

111 Pioglitazone exerted its positive effect by inhibition o

112 Pioglitazone exhibited improved glucose uptake within 3

113 hemoattractant factors after only 10 days of pioglitazone, followed by a 69% reduction in ATM content

114 ion, and patients who undergo treatment with pioglitazone for longer durations (>12 months) or are ad

115 Within each stratum, the efficacy of pioglitazone for preventing stroke or MI was calculated.

116 a double-blind, placebo-controlled trial of pioglitazone for secondary prevention.

117 nd showed that feeding the PPARgamma agonist pioglitazone greatly decreased the size of the primary t

118 either the vitamin E group (P = 0.34) or the pioglitazone group (P = 0.29).

119 5-year risk for stroke or MI was 6.0% in the pioglitazone group among patients at lower baseline risk

120 rance occurred in 48% of the patients in the pioglitazone group and 28% of those in the placebo group

121 or type 2 diabetes mellitus were 2.1% in the pioglitazone group and 7.6% in the placebo group, and th

122 ared mean 3MS score increased by 0.27 in the pioglitazone group and by 0.29 in the placebo group (mea

123 curred in 175 of 1939 patients (9.0%) in the pioglitazone group and in 228 of 1937 (11.8%) in the pla

124 After 16 weeks, compared to placebo, the pioglitazone group had a significant reduction in Adipo-

125 ts at higher risk, the risk was 14.7% in the pioglitazone group vs 19.6% for placebo (absolute risk d

126 zard ratio for conversion to diabetes in the pioglitazone group was 0.28 (95% confidence interval, 0.

127 %) in the placebo group (hazard ratio in the pioglitazone group, 0.76; 95% confidence interval [CI],

128 alysis revealed that while rosiglitazone and pioglitazone had little effect on gene changes induced b

129 Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in

130 The results suggest that pioglitazone has direct metabolic deceleration effects o

131 stion with a high-fat diet (HFD) or HFD plus pioglitazone (HFD-P), we demonstrate that the fractions

132 arably to high-dose glucocorticoids, whereas pioglitazone + high-dose glucocorticoids reduced protein

133 re benefit from the insulin-sensitizing drug pioglitazone hydrochloride compared with patients at low

134 , 850 to 1500 mg/d, and 10 patients received pioglitazone hydrochloride, 15 to 30 mg/d; 20 untreated

135 or MetS, such as metformin hydrochloride and pioglitazone hydrochloride, have been demonstrated, alth

136 amyloid-lowering capabilities to the racemic pioglitazone in an in vitro AD model.

137 oglitazone was 46.6% higher than that of (-)-pioglitazone in brain tissue and 67.7% lower than that o

138 GIIS) and oxygen consumption were reduced by pioglitazone in isolated islets and INS832/13 cells.

139 re, the binding of the type II diabetes drug pioglitazone in mitoNEET effectively inhibits the thiol-

140 rain tissue and 67.7% lower than that of (-)-pioglitazone in plasma.

141 ent of NASH include the use of vitamin E and pioglitazone, in addition to dietary counseling and regu

142 ormed a secondary analysis of the effects of pioglitazone, in comparison with placebo, on acute coron

143 he remaining PPARgamma in Pparg(C/-) mice by pioglitazone increased S1P1 levels, reduced the Th17 pop

144 In terms of population regions, pioglitazone increased the risk for bladder cancer could

145 Pioglitazone increased weight less among patients at hig

146 al years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer.

147 Our data show that pioglitazone induced cellular lipid accumulation and the

148 Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were

149 In vitro, pioglitazone inhibited both alloantigen-induced prolifer

150 activated receptor ligands rosiglitazone and pioglitazone inhibited CYP26A1 with IC(50) values of 3.7

151 The diabetes drug pioglitazone inhibits iron transfer from WT mNT to mitoc

152 Dosing with (+)-pioglitazone instead of the racemic mixture may result i

153 Microinjection of pioglitazone into the AMY, but not into the HIPP, abolis

154 his finding, site-specific microinjection of pioglitazone into the RMTg but not into the VTA reduced

155 sting additional models of ALS, we find that pioglitazone is also neuroprotective when FUS, but not S

156 Pioglitazone is beneficial in improving liver histology

157 Pioglitazone is contraindicated in patients with HF>New

158 Pioglitazone is currently undergoing clinical trials for

159 nhibitor (imatinib) and a thiazolidinedione (pioglitazone) is proposed for the treatment of chronic m

160 oNEET, a target of the type II diabetes drug pioglitazone, is a key regulator of energy metabolism in

161 Dosing mice with pure (+)-pioglitazone led to a 76% increase in brain exposure lev

162 g of the thiazolidinedione antidiabetic drug pioglitazone led to the discovery of a novel outer mitoc

163 Remarkably, pioglitazone + low-dose glucocorticoids also reduced pro

164 If diabetes patients used pioglitazone <8 quarters, the dementia risk was comparab

165 uction of [2Fe-2S] clusters, suggesting that pioglitazone may modulate the function of mitoNEET by bl

166 enhanced glycolysis in the cytosol and that pioglitazone may regulate energy metabolism in mitochond

167 bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.

168 after oxygen-glucose deprivation, as well as pioglitazone-mediated cerebrovascular protection in a mo

169 tic cancer risks associated with ever use of pioglitazone merit further investigation to assess wheth

170 ntrast, treatment with the PPARgamma agonist pioglitazone mimicked selenium supplementation.

171 and the long-term effects (>/=3.6 years) of pioglitazone needs be monitored more carefully.

172 tors associated with the favorable effect of pioglitazone on atheroma progression.

173 It can be assumed that the effects of pioglitazone on beta-cells are negligible under in vivo

174 We tested the influence of troglitazone and pioglitazone on different parameters of SSC, including i

175 nglion neurons revealed a salutary effect of pioglitazone on pathways related to defense and cytokine

176 for ischemic stroke to examine the effect of pioglitazone on stroke outcomes.

177 Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated

178 events in this population and the impact of pioglitazone on these events have not been described.

179 the temporal relationship of the effects of pioglitazone on these two parameters.

180 ic conditions, to investigate the effects of pioglitazone on TNFalpha, SOCS3, and downstream insulin

181 nediones (TZDs), including rosiglitazone and pioglitazone, on cardiac tissue.

182 ct of two TZD class drugs, rosiglitazone and pioglitazone, on human aortic smooth muscle cell (SMC) e

183 th coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCO

184 Pioglitazone or its analog NL-1 appears to inhibit the e

185 Pioglitazone or matching placebo.

186 2 patients were randomly assigned to receive pioglitazone or placebo.

187 fits of lifestyle modification alone or with pioglitazone or vitamin E in a cohort of patients aged 5

188 le modification alone, treatment with either pioglitazone or vitamin E in addition to lifestyle modif

189 siglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively

190 nhibitor vildagliptin, the thiazolidinedione pioglitazone, or placebo for 3 months in addition to lif

191 sulin glargine, insulin lispro, liraglutide, pioglitazone, or sitagliptin).

192 utic options such as lifestyle modification, pioglitazone, or vitamin E.

193 The PPARgamma agonist pioglitazone partially rescued the adipogenic defect in

194 ing glitazone drugs, rosiglitazone (ROS) and pioglitazone (PGZ) both have anti-proliferative and anti

195 Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observ

196 d diet with or without the PPARgamma agonist pioglitazone (Pio) (20 mg/kg per day) for 5 weeks.

197 rator-activated receptor (PPARgamma) ligands pioglitazone (Pio) or rosiglitazone (Rosi) to TGF-beta-t

198 Whereas rosiglitazone and pioglitazone potentiated cell death, troglitazone acted

199 ent showed improved molecular responses with pioglitazone, presumably through PPARgamma activation an

200 onstrate that the primary mechanism by which pioglitazone protects against polymicrobial sepsis is th

201 In this regard, pioglitazone provides advantages as a therapeutic tool,

202 Patients randomized to pioglitazone received the drug during a 16-week run-in p

203 5-deoxy-prostaglandin-J(2), ciglitazone, and pioglitazone reduced intimal expansion, intimal infiltra

204 Pioglitazone reduced risk for ischemic strokes (HR, 0.72

205 ondiabetics, the cumulative long-term use of pioglitazone reduced the dementia risk by 47% (RR = 0.53

206 Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of

207 nsulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndrom

208 Pioglitazone reduced the risk of acute coronary syndrome

209 As compared with placebo, pioglitazone reduced the risk of conversion of impaired

210 Similarly, pioglitazone reduced the risk of large MIs with serum tr

211 demonstrate that activation of PPARgamma by pioglitazone reduces the motivation for heroin and atten

212 Surprisingly, pioglitazone repressed TTF-1 expression in PPFP-expressi

213 Both metformin and pioglitazone resulted in a significant increase in the n

214 ral treatment of APPswe/PS1Deltae9 mice with pioglitazone resulted in dramatic reductions in brain le

215 Treatment with pioglitazone, rosiglitazone, or dexamethasone significan

216 onectin protein concentration contributes to pioglitazone's ability to enhance HMW adiponectin levels

217 acceptor proteins and support the idea that pioglitazone's antidiabetic mode of action may, in part,

218 We also evaluated pioglitazone's effects on retinal function using electro

219 e treated with metformin and 10 who received pioglitazone showed a significant decrease in the number

220 beta cells, as islets from mice treated with pioglitazone showed reductions in PPAR-gamma (Ser-273) p

221 Patients treated with pioglitazone showed significant decreases in the mean (S

222 acrophages treated with a PPARgamma agonist (pioglitazone) showed enhanced phagocytosis and bacterial

223 Data demonstrate that 2 months of pioglitazone significantly increased electroretinogram a

224 demonstrated that (PPARgamma) activation by pioglitazone significantly inhibited both oxygen-glucose

225 Treatment with the PPARgamma agonist pioglitazone significantly reduced TFH cell responses in

226 Pioglitazone slowed progression compared with glimepirid

227 found that the synthetic PPARgamma agonist, pioglitazone, stimulated Abeta degradation by both micro

228 Additional studies with pioglitazone suggest that mitochondrial copper is target

229 menstrual cycle of females was inhibited by pioglitazone, suggesting that an estrogen-sufficient env

230 ed in both REC and Muller cells treated with pioglitazone, suggesting that these two cell types are k

231 lipoprotein cholesterol levels compared with pioglitazone, sulfonylureas, and DPP-4 inhibitors.

232 nt ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo.

233 ent ischemic stroke or TIA to receive either pioglitazone (target dose, 45 mg daily) or placebo.

234 rction was lower among patients who received pioglitazone than among those who received placebo.

235 Weight gain was greater with pioglitazone than with placebo (3.9 kg vs. 0.77 kg, P<0.

236 rthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NA

237 When mice were dosed with racemic pioglitazone, the concentration of (+)-pioglitazone was

238 Pioglitazone therapy was also associated with a decrease

239 result in higher levels of brain exposure to pioglitazone, thus potentially improving the development

240 nse to pioglitazone, and that the ability of pioglitazone to decrease TTF-1 expression contributes to

241 evel was combined with the administration of pioglitazone to simulate the clinical aggressive lipid m

242 child with refractory NS by the addition of pioglitazone to the treatment correlated with marked red

243 rays of large myelinated sciatic nerves from pioglitazone-treated animals revealed an unanticipated i

244 Pioglitazone-treated mice showed identical weight gain,

245 cytokine production and high IL-10 levels in pioglitazone-treated mice.

246 Pioglitazone-treated patients demonstrated greater incre

247 logy independent of changes in Adipo-IR, and pioglitazone treatment acutely improved Adipo-IR, but th

248 Pioglitazone treatment also was associated with improvem

249 ence for age effects, nor for selection into pioglitazone treatment due to obesity.

250 p = 0.317), and diabetes patients without a pioglitazone treatment had a 23% increase in dementia ri

251 Pioglitazone treatment improved hemoglobin A1c (HbA1c),

252 n a murine model of sepsis, we now show that pioglitazone treatment improves microbial clearance and

253 These findings indicate that pioglitazone treatment is associated with a reduced deme

254 Long-term pioglitazone treatment is safe and effective in patients

255 Moreover, although pioglitazone treatment normalized renal function, it had

256 hus potentially improving the development of pioglitazone treatment of AD.

257 Pioglitazone treatment of BKS db/db mice produced a sign

258 We sought to determine whether pioglitazone treatment of gp91(phox-/-) mice enhanced ph

259 It was hypothesized that pioglitazone treatment of gp91(phox-/-) mice, a murine m

260 The effect of 10 and 21 days of pioglitazone treatment on insulin sensitivity in 26 diab

261 Sildenafil or pioglitazone treatment prevented proteinuria and the inc

262 Pioglitazone treatment resulted in the phenotypic polari

263 concentrations of all oligomers increased on pioglitazone treatment, with the largest fold increase b

264 ollowed by an 18-month open-label phase with pioglitazone treatment.

265 nocytes from patients with CGD after ex vivo pioglitazone treatment.

266 n hyperplastic mechanism of weight gain with pioglitazone treatment.

267 titumor effect correlates with the fact that pioglitazone turns PPFP into a strongly PPARgamma-like m

268 We also investigate the stereoselectivity of pioglitazone uptake in the brain.

269 ntial increased risk for bladder cancer with pioglitazone use >/=3 years could not be excluded (OR: 1

270 risk (RR) of dementia incidence dependent on pioglitazone use adjusted for sex, age, use of rosiglita

271 Studies suggest pioglitazone use may increase risk of cancers.

272 Pioglitazone use was not associated with a statistically

273 sults were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% am

274 Crude incidences of bladder cancer in pioglitazone users and nonusers were 89.8 and 75.9 per 1

275 idences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 8

276 The PIVENS (Pioglitazone versus Vitamin E versus Placebo for the Tre

277 hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% confidence interval [CI], 0.9

278 cemic pioglitazone, the concentration of (+)-pioglitazone was 46.6% higher than that of (-)-pioglitaz

279 Pioglitazone was also associated with a lower risk of di

280 Pure (+)-pioglitazone was also shown to have comparable amyloid-l

281 Pioglitazone was associated with a greater frequency of

282 Long-term use of pioglitazone was associated with a lower dementia incide

283 Pioglitazone was associated with a reduced risk for any

284 8 of the 10 additional cancers; ever use of pioglitazone was associated with increased risk of prost

285 Pioglitazone was effective for secondary prevention of i

286 When pioglitazone was given temporarily to three CML patients

287 The effect of pioglitazone was independent of actions on T cells, as p

288 Pioglitazone was less effective than troglitazone on all

289 In a direct comparison, pioglitazone was more cost-effective than vitamin E (ICE

290 Ever use of pioglitazone was not associated with bladder cancer risk

291 Sensitivity analyses indicated that pioglitazone was not cost-effective if either the total

292 is response to rosiglitazone and possibly to pioglitazone was PPARgamma-dependent.

293 or colorectal cancer, rosiglitazone, but not pioglitazone, was associated with a significantly reduce

294 LXR agonist GW3965 and the PPARgamma agonist pioglitazone were individually able to increase the leve

295 , and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily inj

296 significantly increases brain penetration of pioglitazone, whereas inhibition of breast cancer resist

297 The TZD pioglitazone, which has been approved by the U.S. Food a

298 rdial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might

299 New medications are being explored, such as pioglitazone, which is under study for its role in enhan

300 Coadministration of pioglitazone with peginterferon/ribavirin improves insul